News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021
News Features Roughly 80% of ESC Guideline Writers Have Financial COIs Michael O'Riordan April 01, 2021
News Features The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine Shelley Wood October 22, 2018
News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017
News Features COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict Todd Neale September 15, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Features PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data Michael O'Riordan January 25, 2016
News Features Despite New Findings, Optimal DAPT Duration Still Up in the Air Todd Neale December 10, 2014